Enbrel ex-McKinsey nerd

No matter how smart you, where you went to school, how good looking you are, God lets those who have humility and treat all living beings with respect into Heaven.

 

What will JC do to get to that VP amgen title? More INBU layoffs?

 

JC is looking to be an RD or VP of sales so he can check the box for field experience and punish the Enbrel reps. He wants to get rid of stale reps for his robots.

 

JC addicted to power like Harvey Weinstein is to sex

 

The bluetooth auto-injector will save the day

 

There are over 12k views on Jay...do that many people at Amgen even know him?

 

Wow. Pretty clear to me that Amgen is rotting because of moronic r.acists like the poster above.


.

 

Regardless of this mans ethnic origins, he’s unqualified because he has no real field experience and no true marketing experience. McKinsey experience and MIT degree doesn’t mean shit. Amgen is full of these fancy slide making hacks that add no value.

 

will this save Enbrel? Will access improve compared to Humira? Will derm soar because of this new device?


Amgen, Inc. announced the launch of its Enbrel Mini with AutoTouch, a new auto injector device for Enbrel in the United States.

The Enbrel Mini single-dose prefilled cartridges, used with the AutoTouch reusable autoinjector device, provide an additional administration option for rheumatoid arthritis drug Enbrel. The Enbrel Mini with AutoTouch device was approved by the FDA in September.

 

Two words: elitist narcassist

 

Couldn’t get into Harvard

 

Culture killer

 

Pure evil

 

Jay is nothing but a backstabber. Stay away from this self center asshole.

 

Looks like JC is trying to hide by keeping Linkedin title at Amgen "Executive Director - Global Marketing" and his location as San Francisco Bay Area.

 

Why keep bashing JC. He’s managements pet and will be a TP and a VP soon. Then he will get the entire INBU replaced.

 

Two face is his name

 

These are the recent PsO results:

JNJ’s Tremfya (IL-23) is at 13.6% NRX SHARE HAS ALREADY OVERTAKEN BOTH
Novartis’ Cosentyx (9.3%) and Lilly’s Taltz (7.0%), DESPITE HAVING JUST LAUNCHED IN
3Q17. NEVERTHELESS, THE il-17 CLASS HAS GROWN TO A 17.4% SHARE VS. 15.1%
A YEAR AGO WITH THE RECENT ADDITION OF Valeant’s SILIQ. CELGENE’s OTEZLA REMAINS THE
OVERALL NRX LEADER WITH A 30% SHARE, WHICH IS FLAT FROM A YEAR AGO. NET SHARE LOSERS INCLUDE STELARA (-831 bps) and Amgen’s ENBREL (-406 BPS), WHILE JnJ OVERALL HAS GAINED +530 BPS OF SHARE IN PSO.

Amgen would be worse but there isn't much share left to lose. How will anyone fix this? No McKinsey magic here.

 

Who would have ever thought that over 100 post from all departments at Amgen and McKinsey would be devoted to trashing this man. The number of views is getting near the number of employees at Amgen.

 

He brought it on himself. His behavior. His attitude.